On August 8, Elanco Animal Health Inc declined 8.88% in regular trading, trading at 22.13 USD/share, with turnover of $441 million. The stock has now fallen sharply for two consecutive sessions following its Q2 earnings release, fully erasing the 9.4% surge seen on August 5.

On August 5, the company reported Q2 adjusted EPS of $0.34, significantly exceeding the consensus estimate of $0.27, representing a 30.8% year-over-year increase. Revenue of $1.368 billion also beat the $1.313 billion estimate, growing 10.5% year-over-year. The company raised its full-year guidance to adjusted EPS of $1.10-$1.16 and revenue of $5.09-$5.14 billion, both above analyst expectations. Despite the strong results and UBS raising its price target to $33 from $31 with a maintained Buy rating, the stock has experienced aggressive selling over two sessions, declining approximately 7.55% on August 7 and another 8.88% on August 8.

Sector peer Zoetis also fell 5.94% on the same day, suggesting broader animal health sector pressure compounding the post-earnings profit-taking in Elanco shares.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)